Rome, 1 October 2021 – Una antiviral pill which halves the effects of Covid. A breakthrough in the fight against the virus could soon come. The pharmaceutical company Merck announced today i results phase 3 of one clinical study which shows how molnupiravir (this is the name of their drug) reduce the risk by 50% to be hospitalized to the hospital or to die.
Covid in Italy. the bulletin of 1 October
The research involved 775 volunteers in the United States and abroad. In detail, 7% of the group of volunteers who received the drug were hospitalized and none of them died, against a hospitalization and death rate of 14%, including eight deaths, recorded in the group that received the drug. placebo.
The American pharmaceutical company has made it known that it will ask the Food and Drugs Administration US that the drug is authorized. If it gets the green light from the FDA, it would be the first drug of its kind: a pill to be taken twice a day, for five days, to be prescribed to patients in the early stages of the disease.
The publication of Merck’s study comes a few days after the announcement of the other giant Pfizer of the start of the experimentation of a oral medication designed to prevent Covid-19 in those who have been exposed to the virus, exactly how do intramuscular vaccines do.
Read also: Rt Italia index stable at 0.83, the incidence decreases
© All rights reserved